// App-Quantinova.ai

2531 : ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors.

Researchers

Presenter

  • Essam Ahmed Ghazaly

Principal Investigators

  • Ivana Rizzuto

  • Harpreet Wasan

  • Christopher McGuigan

  • Sarah Patricia Blagden

  • Hani Gabra

  • Nagy A Habib

  • Robert C. F. Leonard

Medical Centers

  • NIHR/Wellcome Trust Imperial Clinical Research Facility, Imperial College, London, United Kingdom

  • Department of Oncology, Imperial College, London, United KingdomCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United KingdomNIHR/Wellcome Trust Imperial Clinical Research Facility and Department of Oncology, Imperial College, London, United Kingdom

  • School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Acelarin

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT01621854

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved